Fournier's gangrene in patients with type 2 diabetes using second‐line antidiabetic medications-Reference-Cited by-同舟云学术

Fournier's gangrene in patients with type 2 diabetes using second‐line antidiabetic medications

Published:2019-10-13 Issue:2 Volume:22 Page:267-271
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Petruski‐Ivleva Natalia¹,Schneeweiss Sebastian²,Eapen Sara¹,Rajan Aditya¹,Jan Saira³⁴

Affiliation:

1. ScienceAetion, Inc New York New York

2. Division of PharmacoepidemiologyDepartment of Medicine and Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts

3. Pharmacy Strategy and Clinical IntegrationHorizon Healthcare Services Inc. Newark New Jersey

4. School of PharmacyRutgers State University of New Jersey New Brunswick New Jersey

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13886

Reference10 articles.

1. US Food and Drug Administration(FDA). Safety Announcement: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes.2018.https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm. Accessed September 20 2018.

2. Fournier's Gangrene: Population Based Epidemiology and Outcomes

3. Outcomes from treatment of necrotizing soft-tissue infections: results from the National Surgical Quality Improvement Program database

4. Fournier's Gangrene: Epidemiology and Outcomes in the General US Population

5. Contemporary trends in necrotizing soft-tissue infections in the United States

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of Urogenital Bacterial Infection with Sodium-Glucose Cotransporter-2 Inhibitors: A Retrospective Cohort Study Using a Claims Database;Diabetes Therapy;2024-07-03

2. Fournier's Gangrene in a Patient With CKD Without Diabetes Possibly Related to Sodium-Glucose Cotransporter 2 Inhibitor Therapy;Kidney International Reports;2024-05

3. Physicians’ Considerations and Practice Recommendations Regarding the Use of Sodium-Glucose Cotransporter-2 Inhibitors;Journal of Clinical Medicine;2022-10-13

4. Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach;Diabetes, Obesity and Metabolism;2022-03-24

5. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of urosepsis: A multi‐site, prevalent new‐user cohort study;Diabetes, Obesity and Metabolism;2020-06-04